Adipose-Derived Mesenchymal Stem Cells Enhance Ovarian Cancer Growth and Metastasis by Increasing Thymosin Beta 4X-Linked Expression.

Chu Y, You M, Zhang J, Gao G, Han R, Luo W, Liu T, Zuo J, Wang F

Stem cells international20 Oct 2019Cited by 30 (Europe PMC)

PMID31781249PMCIDPMC6855023DOI10.1155/2019/9037197PepBankPUB-31781249

Summary

As shown in our previous studies, growth and metastasis of ovarian cancer can be regulated by adipose-derived mesenchymal stem cells (ADSCs). However, the underlying mechanism has not yet been revealed. In this study, a proteomics analysis was performed to compare protein expression treated with and without ADSCs in ovarian cancer cells. Protein levels were altered in ovarian cancer cells due to the treatment of ADSCs. Thymosin beta 4 X-linked (TMSB4X) levels changed dramatically, and this protein was identified as one of the most important candidate molecules contributing to the tumour-promoting effects of ADSCs. Compared with the cells that are cultured in the normal growth medium, the TMSB4X levels cultured in ADSC-conditioned medium increased significantly in ovarian cancer cells. Furthermore, the growth and invasion of cancer cells were decreased, even in the ADSC-conditioned medium treatment group (P < 0.05), by the inhibition of TMSB4X. As shown in the bioluminescence images captured in vivo, increased ovarian cancer's growth and metastasis, along with elevated TMSB4X expression, were observed in the group of ADSC-conditioned medium, and the tumour-promoting effect of ADSCs was attenuated by the inhibition of TMSB4X. Based on our findings, increased TMSB4X expression may play a role in accelerating the ADSC-mediated proliferation, invasion, and migration of ovarian cancers.

CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study6

No result from this study comes from a test of the peptide.

Natural levels measured2

These results measure the body's own peptide. Nobody was given the peptide. They are not evidence about taking it. They are left out of key results, evidence counts and charts.

01AnimalEndogenous levelAnimal study (in vivo)Other
In vivo, TMSB4X expression was elevated in the ADSC-conditioned medium group.
In plain wordsIn an animal ovarian cancer model, the body's own thymosin beta‑4 X-linked levels were higher in the group given medium from fat-derived stem cells.
Peptide
Thymosin beta-4 (human)
Outcome
IncreaseTMSB4X expression in vivo with ADSC-conditioned medium
Study
n: not reported in source
Ovarian cancer in vivo (bioluminescence imaging)
Outcome group
Tumor growth · Cancer
Source sentences
Summary
increased ovarian cancer's growth and metastasis, along with elevated TMSB4X expression, were observed in the group of ADSC-conditioned medium, and the tumour-promoting effect of ADSCs was attenuated by the inhibition of TMSB4X.
1 context sentence(design, population, supporting numbers)
Summary · context
In this study, a proteomics analysis was performed to compare protein expression treated with and without ADSCs in ovarian cancer cells.
This result measures the body's own Thymosin beta-4 (human). Nobody was given the peptide. It is not evidence about taking it.
Show in the study text Report a problemFND-3178124904
02LabEndogenous levelIn vitro (cells)Other
In ovarian cancer cells, TMSB4X levels increased significantly in ADSC-conditioned medium compared with normal growth medium.
In plain wordsIn ovarian cancer cells, the body's own thymosin beta‑4 X-linked levels rose in medium from fat-derived stem cells.
Peptide
Thymosin beta-4 (human)
Outcome
IncreaseTMSB4X level in ovarian cancer cells cultured in ADSC-conditioned medium
Study
n: not reported in source
Ovarian cancer cells in adipose-derived stem cell (ADSC) conditioned medium
Comparator
Normal growth medium
Outcome group
Tumor growth · Cancer
Source sentences
Summary
Compared with the cells that are cultured in the normal growth medium, the TMSB4X levels cultured in ADSC-conditioned medium increased significantly in ovarian cancer cells.
1 context sentence(design, population, supporting numbers)
Summary · context
In this study, a proteomics analysis was performed to compare protein expression treated with and without ADSCs in ovarian cancer cells.
This result measures the body's own Thymosin beta-4 (human). Nobody was given the peptide. It is not evidence about taking it.
Show in the study text Report a problemFND-3178124901

Studies that did not test the peptide alone4

In this study, Thymosin beta-4 (human) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Thymosin beta-4 (human).

03AnimalNot a test of Thymosin beta-4 (human) aloneAnimal study (in vivo)Mechanism
In vivo, the tumour-promoting effect of ADSCs on ovarian cancer growth was attenuated by inhibition of TMSB4X.
In plain wordsIn an animal ovarian cancer model, blocking thymosin beta‑4 X-linked reduced the tumour growth driven by fat-derived stem cells.
Peptide
Thymosin beta-4 (human)
Outcome
DecreaseTumour growth after TMSB4X inhibition in vivo
Study
n: not reported in source
Ovarian cancer in vivo (bioluminescence imaging)
Outcome group
Tumor growth · Cancer
Source sentences
Summary
As shown in the bioluminescence images captured in vivo, increased ovarian cancer's growth and metastasis, along with elevated TMSB4X expression, were observed in the group of ADSC-conditioned medium, and the tumour-promoting effect of ADSCs was attenuated by the inhibition of TMSB4X.
1 context sentence(design, population, supporting numbers)
Summary · context
In this study, a proteomics analysis was performed to compare protein expression treated with and without ADSCs in ovarian cancer cells.
In this study, Thymosin beta-4 (human) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin beta-4 (human).
Show in the study text Report a problemFND-3178124905
04AnimalNot a test of Thymosin beta-4 (human) aloneAnimal study (in vivo)Mechanism
In vivo, the tumour-promoting effect of ADSCs on ovarian cancer metastasis was attenuated by inhibition of TMSB4X.
In plain wordsIn an animal ovarian cancer model, blocking thymosin beta‑4 X-linked reduced the spread driven by fat-derived stem cells.
Peptide
Thymosin beta-4 (human)
Outcome
DecreaseMetastasis after TMSB4X inhibition in vivo
Study
n: not reported in source
Ovarian cancer in vivo (bioluminescence imaging)
Outcome group
Tumor growth · Cancer
Source sentences
Summary
As shown in the bioluminescence images captured in vivo, increased ovarian cancer's growth and metastasis, along with elevated TMSB4X expression, were observed in the group of ADSC-conditioned medium, and the tumour-promoting effect of ADSCs was attenuated by the inhibition of TMSB4X.
1 context sentence(design, population, supporting numbers)
Summary · context
In this study, a proteomics analysis was performed to compare protein expression treated with and without ADSCs in ovarian cancer cells.
In this study, Thymosin beta-4 (human) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin beta-4 (human).
Show in the study text Report a problemFND-3178124906
05LabNot a test of Thymosin beta-4 (human) aloneIn vitro (cells)Mechanism
In ovarian cancer cells, inhibition of TMSB4X decreased cell growth, even in ADSC-conditioned medium.
In plain wordsIn ovarian cancer cells, blocking thymosin beta‑4 X-linked reduced growth, even in medium from fat-derived stem cells.
Peptide
Thymosin beta-4 (human)
Outcome
DecreaseCancer cell growth after TMSB4X inhibition
Study
n: not reported in source
Ovarian cancer cells in ADSC-conditioned medium
Comparator
ADSC-conditioned medium without TMSB4X inhibition
Outcome group
Tumor growth · Cancer
Source sentences
Summary
Furthermore, the growth and invasion of cancer cells were decreased, even in the ADSC-conditioned medium treatment group (P < 0.05), by the inhibition of TMSB4X.
1 context sentence(design, population, supporting numbers)
Summary · context
In this study, a proteomics analysis was performed to compare protein expression treated with and without ADSCs in ovarian cancer cells.
In this study, Thymosin beta-4 (human) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin beta-4 (human).
Show in the study text Report a problemFND-3178124902
06LabNot a test of Thymosin beta-4 (human) aloneIn vitro (cells)Mechanism
In ovarian cancer cells, inhibition of TMSB4X decreased invasion, even in ADSC-conditioned medium.
In plain wordsIn ovarian cancer cells, blocking thymosin beta‑4 X-linked reduced invasion, even in medium from fat-derived stem cells.
Peptide
Thymosin beta-4 (human)
Outcome
DecreaseCancer cell invasion after TMSB4X inhibition
Study
n: not reported in source
Ovarian cancer cells in ADSC-conditioned medium
Comparator
ADSC-conditioned medium without TMSB4X inhibition
Outcome group
Tumor growth · Cancer
Source sentences
Summary
Furthermore, the growth and invasion of cancer cells were decreased, even in the ADSC-conditioned medium treatment group (P < 0.05), by the inhibition of TMSB4X.
1 context sentence(design, population, supporting numbers)
Summary · context
In this study, a proteomics analysis was performed to compare protein expression treated with and without ADSCs in ovarian cancer cells.
In this study, Thymosin beta-4 (human) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin beta-4 (human).
Show in the study text Report a problemFND-3178124903

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
13 Oct 2026, 01:52 UTC
Study results updated
Version 1
12 Oct 2026, 18:17 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

PepBank is a research reference. Talk to a doctor before you use any peptide.